Kumar Neil 4
4 · BridgeBio Pharma, Inc. · Filed May 26, 2026
Research Summary
AI-generated summary of this filing
BridgeBio (BBIO) CEO Neil Kumar Sells 26,103 Shares
What Happened
- Neil Kumar, CEO of BridgeBio Pharma (BBIO), sold a total of 26,103 shares in open-market transactions on May 21, 2026, generating aggregate proceeds of approximately $1,812,522.
- Individual transactions reported:
- 2,256 shares at $67.57 — $152,435
- 6,725 shares at $68.30 — $459,334
- 5,072 shares at $69.22 — $351,102
- 11,250 shares at $70.48 — $792,916
- 800 shares at $70.92 — $56,735
- These were sales (code S) — routine disposition of shares rather than purchases (not a bullish signal).
Key Details
- Transaction date: May 21, 2026. Form 4 filed: May 26, 2026 (appears filed after the typical 2-business-day window for Form 4s).
- Prices: sales executed across price ranges from ~$66.81 to $70.97 per share (weighted-average ranges are footnoted in the filing).
- Total shares sold: 26,103; total proceeds: ≈ $1.81 million.
- Notable footnotes:
- F1: Sales were effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025 (pre-scheduled trading plan).
- F2–F6: Filing reports weighted-average sale-price ranges and offers to provide per-price breakdowns on request.
- F7: Reporting person disclaims beneficial ownership except to extent of pecuniary interest.
- Shares owned after the transaction: not specified in the information provided.
Context
- Sales under a 10b5-1 plan are typically pre-arranged and can be routine (the plan reduces the implication that the insider traded on inside information).
- Because these are outright sales (code S), they indicate liquidation of holdings rather than a vote of confidence via purchase.
Insider Transaction Report
Form 4
Kumar Neil
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-05-21$67.57/sh−2,256$152,435→ 267,174 total - Sale
Common Stock
[F1][F3]2026-05-21$68.30/sh−6,725$459,334→ 260,449 total - Sale
Common Stock
[F1][F4]2026-05-21$69.22/sh−5,072$351,102→ 255,377 total - Sale
Common Stock
[F1][F5]2026-05-21$70.48/sh−11,250$792,916→ 244,127 total - Sale
Common Stock
[F1][F6]2026-05-21$70.92/sh−800$56,735→ 243,327 total
Holdings
- 555,686(indirect: By Trust)
Common Stock
[F7] - 4,358,447(indirect: By Trust)
Common Stock
[F7]
Footnotes (7)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
- [F2]Represents the weighted average sale price of the shares sold from $66.81 to $67.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F3]Represents the weighted average sale price of the shares sold from $67.81 to $68.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F4]Represents the weighted average sale price of the shares sold from $68.81 to $69.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F5]Represents the weighted average sale price of the shares sold from $69.86 to $70.85 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F6]Represents the weighted average sale price of the shares sold from $70.86 to $70.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- [F7]The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Signature
/s/ Laura Woodhead, Attorney-in-Fact|2026-05-26